| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
FASN-IN-1 targets fatty acid synthase (FASN), a key enzyme in the fatty acid synthesis pathway. By blocking FASN activity, the compound suppresses lipid synthesis required for rapid cell growth and survival, making it a potential therapeutic agent for cancer and metabolic diseases.
|
|---|---|
| ln Vitro |
In vitro, FASN-IN-1 effectively inhibits FASN activity, leading to reduced fatty acid synthesis in cancer cells. The compound is extracted from patent WO2015134790A1 (compound 56). Detailed in vitro potency data (IC₅0 values) are available in the patent literature.
|
| ln Vivo |
In vivo data for FASN-IN-1 are limited. As a FASN inhibitor, the compound is expected to suppress tumor growth by depriving cancer cells of lipids required for membrane synthesis and energy production. Detailed in vivo efficacy studies are described in the primary patent literature.
|
| Enzyme Assay |
For in vitro enzyme binding assays, FASN-IN-1 is evaluated using recombinant FASN enzyme in activity assays. The compound is incubated with FASN and substrates (acetyl-CoA, malonyl-CoA, and NADPH), and the rate of fatty acid synthesis is measured spectrophotometrically. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cellular assays, FASN-IN-1 is dissolved in DMSO and applied to cancer cell lines. Cellular lipid synthesis, FASN activity, cell proliferation, and apoptosis are assessed using radiolabeled acetate incorporation, Oil Red O staining, MTT assays, or flow cytometry.
|
| Animal Protocol |
In vivo animal studies with FASN-IN-1 typically involve oral or intraperitoneal administration in mouse xenograft models of cancer. Tumor growth inhibition, body weight, and plasma lipid levels are monitored. Detailed protocols are described in the patent literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for FASN-IN-1 are limited. The compound has a molecular weight of 395.54 and is soluble in DMSO at 90 mg/mL. It should be stored as a powder at -20degC for up to 3 years or at 4degC for 2 years.
|
| Toxicity/Toxicokinetics |
Toxicology data for FASN-IN-1 are limited. As a metabolic enzyme inhibitor, the compound may affect normal lipid metabolism; careful dose optimization is required. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| References | |
| Additional Infomation |
FASN-IN-1 (CAS#: 1808260-84-5) has the molecular formula C1₈H2₅N3O3S2 and molecular weight 395.54. The chemical name is 1-({4-[4-(diethylsulfamoyl)phenyl]-1,3-thiazol-2-yl}carbamoyl)-1-methylpropyl. It is a research reagent only.
|
| Molecular Formula |
C18H25N3O3S2
|
|---|---|
| Molecular Weight |
395.539401769638
|
| Exact Mass |
395.133
|
| CAS # |
1808260-84-5
|
| PubChem CID |
118356203
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
26
|
| Complexity |
553
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N(C1SC=C(C2C=CC(S(=O)(=O)N(CC)CC)=CC=2)N=1)C(=O)[C@@H](C)CC
|
| InChi Key |
IXMQVFSSASHOGM-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C18H25N3O3S2/c1-5-13(4)17(22)20-18-19-16(12-25-18)14-8-10-15(11-9-14)26(23,24)21(6-2)7-3/h8-13H,5-7H2,1-4H3,(H,19,20,22)/t13-/m0/s1
|
| Chemical Name |
(2S)-N-[4-[4-(diethylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-2-methylbutanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~252.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5282 mL | 12.6409 mL | 25.2819 mL | |
| 5 mM | 0.5056 mL | 2.5282 mL | 5.0564 mL | |
| 10 mM | 0.2528 mL | 1.2641 mL | 2.5282 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
